Lakefront Biotherapeutics (formerly Galapagos) is a Belgian biopharmaceutical company focused on identifying and advancing clinical-stage assets for severe diseases. After years built around small-molecule discovery and later cell therapy, it has refocused on a more capital-disciplined, asset-centric model. Its pipeline orientation includes oncology and immunology opportunities, with external collaborations and dealmaking central to how programs are sourced and progressed.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 75 | — | -153.4 | — |
| Q2 2025 | 65.3 | — | -105.8 | — |
| Q3 2025 | 71.2 | — | -202.1 | — |
| Q4 2025 | 900.8 | — | 782.1 | — |
| Q1 2026 | 6.5 | -91.4% | 14.5 | — |
All markets — KeepWinning global stock screener
Other companies on Euronext Amsterdam: Eurocommercial Properties N.V. (ECMPA), Flow Traders Ltd. (FLOW), Corbion N.V. (CRBN), AMG Critical Materials N.V. (AMG), Fugro N.V. (FUR), Wereldhave N.V. (WHA)